Annexon (ANNX) vs Pharming Group N.V. (PHAR)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 18, 2026.
Summary
Annexon (ANNX) has outperformed Pharming Group N.V. (PHAR) over the past year, gaining 8.3% versus a loss of 33.1%. Over five years, PHAR leads with a -0.6% price change compared with -81.6% for ANNX. Pharming Group N.V. is the larger company by market cap ($662.5 million vs $646.5 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ANNX | PHAR |
|---|---|---|
| Share price | $3.41 | $9.36 |
| Market cap | $646.46M | $662.48M |
| 1-day change | -5.28% | -2.40% |
| YTD return | -32.07% | -47.03% |
| 1-year return | +8.25% | -33.14% |
| 5-year return | -81.56% | -0.64% |
| P/E ratio (TTM) | — | 72.00 |
| Forward P/E | — | 142.90 |
| EPS (TTM) | $-1.13 | $0.13 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $376.13M |
| Revenue growth (YoY) | — | +26.56% |
| Net income (latest FY) | $-206.69M | $2.85M |
| Gross margin | — | 87.90% |
| Operating margin | — | 6.87% |
| Net margin | — | 0.76% |
| 52-week high | $7.18 | $21.34 |
| 52-week low | $2.54 | $9.31 |
| Distance from 52-week high | -52.51% | -56.14% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +352.49% | +266.99% |
| Average volume | 2.90M | 23.08K |
| Shares outstanding | 189.58M | 70.78M |
| Employees | 92 | 407 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ANNX has outperformed PHAR by 41.4 percentage points over the past year.
About Annexon
ANNX stock →Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. The company provides Tanruprubart, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase 2a clinical trial for the treatment of amyotrophic lateral sclerosis.
Health Care · Biotechnology: Pharmaceutical Preparations · 92 employees
About Pharming Group N.V.
PHAR stock →Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company's lead product is RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.
Health Care · Biotechnology: Pharmaceutical Preparations · 407 employees
ANNX vs PHAR FAQ
Which is bigger, Annexon or Pharming Group N.V.?
Pharming Group N.V. (PHAR) is larger, with a market capitalization of $662.48M compared with $646.46M for Annexon (ANNX).
Which stock has performed better over the past year, ANNX or PHAR?
ANNX returned +8.25% over the past 12 months, compared with -33.14% for PHAR (price return, excluding dividends). Past performance does not predict future results.
Are Annexon and Pharming Group N.V. in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.